



THE OFFICIAL MEETING
OF THE JOURNAL OF
CLINICAL PATHWAYS



Get Practical on Pathways

The meeting focused
on the practical
implementation, utilization,
and measurement of
oncology clinical pathways.

OCTOBER 26–28, 2018

Boston



CLINICAL
PATHWAYS
CONGRESS

ENDORSED BY

ASCO[®]
AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Clinical Pathways Congress is for you...

If you're looking to implement
pathway programs

If you're aiming to improve or expand
your pathway program

If you're building your own pathway for
your institution

If you're considering partnering with a
pathways vendor

If you're struggling with incorporating
care coordination across sites of care

If you don't know how to measure outcomes
of your pathways program

**This is the meeting where the oncology
pathways conversation turns to action.**

ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO-sponsored event.

Value-based care is here.

The question now is: How is your organization utilizing pathways to their fullest to realize the most benefit? Enter the Clinical Pathways Congress.

Year 3 of the Congress gets very practical.

It has been designed to dive in and address the operational questions raised by cancer center directors, clinical pathways directors, medical and pharmacy benefit managers, pathway vendors, and other stakeholders about design, development, implementation, utilization, and outcome measurement:

- › How do we best analyze our patient data?
- › How do we incentivize care coordination and pathways adherence?
- › How does our pathway platform compare to others?
- › How do we build, improve, or expand our pathways program?
- › How do we measure outcomes?



2018 Highlights

Connect with experts and other stakeholders on the “hows” of pathways—a roll-up-your-sleeves, ask-the-questions-keeping-you-up-at-night meeting—and gain practical solutions to achieve optimal patient care while successfully supporting new value-based approaches.



Tools and Platforms
to Support
Data Analysis
for Pathway
Development and
Evaluation



Real-World
Experiences
Developing,
Implementing, and
Evaluating Clinical
Pathway Programs



Town Hall with
Clinical Pathways
Congress 2018
Steering Committee
Members



In Year 3, You'll Experience **MORE** Interactive Sessions

How-To Content

Networking Opportunities

“

Given the increasing complexity of oncology care, the need for clinical pathways as a decision support tool for providers has become more critical than ever. The opportunity to hear from thought leaders in the pathway landscape as we develop the next generation of clinical pathways was of immense value.

”

Andrew Hertler, MD, FACP
CHIEF MEDICAL OFFICER, NEW CENTURY HEALTH



Meet the Steering Committee



Alan Balch
PhD

Chief Executive Officer
Patient Advocate Foundation
Hampton, Virginia



Aymen Elfiky
MD, MSC, MBA

Attending Physician, Medical
Oncology
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Harvard Medical School
Boston, Massachusetts



Joan S. McClure
MS

Senior Vice President
Clinical Information and
Publications
National Comprehensive
Cancer Network
Ft. Washington, Pennsylvania



**Sandeep
"Bobby"
Reddy**
MD

Chief Medical Officer
NantHealth
Culver City, California



Robin T. Zon
MD, FACP, FASCO

Vice President, Finance
& Quality Chair
Michiana Hematology-
Oncology, PC
Mishawaka, Indiana

Bring Your Clinical Pathways Team

Registration discounts are available for groups of 3 or more. Please call 844.730.4052.

The Faculty

A Powerful Lineup of Experts Covering Pathway Development, Design & Impact

Linda Bosserman

MD, FASCO, FACP
Clinical Assistant Professor
City of Hope Medical Group, Inc.
Duarte, California

Deborah Christensen

MSN, APRN, AOCNS, HNB-BC
Intermountain Healthcare System
Lead Oncology Navigation
Oncology Nurse Navigator
Intermountain Cancer Center
St. George, Utah

Robert Daly

MD, MBA
Assistant Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer
Center
New York, New York

Stephen B. Edge

MD, FACS, FASCO
Vice President, Healthcare Outcomes
& Policy
Professor of Oncology
Surgeon, Department of Surgical
Oncology, Breast Service
Roswell Park Comprehensive
Cancer Center
Professor of Surgery
Jacobs School of Medicine
University of Buffalo
Buffalo, New York

Andrew Hertler

MD, FACP
Chief Medical Officer
New Century Health
Brea, California

David Hughes

Clinical Data Scientist
Advanced Analytics Group
Seattle Cancer Care Alliance
Seattle, Washington

Barbara L. McAneny

MD, MACP, FASCO
President-Elect
American Medical Association
CEO, New Mexico Cancer Center
CEO, Innovation Oncology Business
Solutions (IOBS)
Albuquerque, New Mexico

Andrew Norden

MD, MPH, MBA
Chief Medical Officer
Cota Healthcare
New York, New York

Ray Page

DO, PhD, FACOI
President & Director of Research
The Center for Cancer and
Blood Disorders
Fort Worth, Texas

Gary Palmer

MD, JD, MBA, MPH
Chief Medical Officer
Tempus, Inc.
Chicago, Illinois

Michael A. Savin

MD
Assistant Professor
Division of Hematology & Medical
Oncology
Oregon Health & Science University
Portland, Oregon

Winston Wong

PharmD
President
W-Squared Group
Longboat Key, Florida

Scientific Agenda

BENCHMARKING & ASSESSMENT

Friday, October 26

Registration

12:00 PM—7:00 PM

Opening Remarks

1:00 PM—1:10 PM



The State of Clinical Pathways: Results from the Inaugural *Journal of Clinical Pathways* Benchmarking Survey

1:10 PM—1:40 PM

Clinical pathways have become an integral part of oncology care and are poised for further expansion in the years to come. At this critical juncture, it's time to take stock of current trends in clinical pathways use in order to determine where to go from here. Join Dr. Winston Wong, Editor-in-Chief of the *Journal of Clinical Pathways*, for a discussion of the findings from a survey of real-world

pathways stakeholders that reveal the current landscape of clinical pathways use in oncology practice. Dr. Wong will also provide an overview of how this year's conference will address the current challenges identified in the survey.

Faculty: Winston Wong, PharmD

Buy or Build? The Pros and Cons of Vendor- and Provider- Developed Pathways with Insights from the ASCO Oncology Pathway Program Assessment

1:40 PM—2:25 PM

The American Society of Clinical Oncology (ASCO) developed ten criteria for high-quality clinical pathways with the goal of ensuring that their development, implementation, and analysis deliver on the promise of value-based, patient-centered care. In early 2018, ASCO released a report assessing the alignment of six commercial vendor pathways programs against their criteria with the goal of helping oncology practices evaluate their own programs or those they are considering for adoption. In this session, Drs. Daly and Zon will discuss how the results of ASCO's assessment can be applied to guide decision-making when developing an internal pathways program or choosing one from an outside vendor.

Faculty: Robert Daly, MD, MBA; Robin T. Zon, MD, FACP, FASCO

Challenges in Pathway Decision- Making Across Phases of Care: Lessons from Ovarian Cancer

2:25 PM—3:10 PM

Clinical pathways provide recommendations for optimal management approaches at different points in the disease course, from initial diagnosis through varying stages of severity, recurrence, or remission. For diseases such as ovarian cancer, in which treatment recurrence is a challenge and long-term maintenance therapy is often required, the clinical and financial implications of long-term treatment may differ from those of other pathway phases. For example, because PARP inhibitors have varying indications within treatment for recurrent disease and maintenance settings, and depend on BRCA status and platinum sensitivity, their placement may rely on the phase of treatment as well as individual patient factors. This session will

use ovarian cancer to illustrate how considerations for pathway decision-making can differ across phases of care.

Integration of Genomics into Clinical Pathways

3:10 PM—3:55 PM

The advent of “precision medicine” has introduced additional complexity into the chemotherapy decision-making process. With the continued defining of tumors by specific genetic mutations and subsequent development of therapies targeting these mutations, it will become increasingly difficult for the community oncologist to commit information to memory. The incorporation of these molecular drivers of therapy into clinical pathways has the potential to provide the oncologist with a web-enabled decision support tool that is readily accessible “at their fingertips.” The use of such pathways can assure the patient that he/she is receiving high-quality care that incorporates the latest scientific advances.

Faculty: Andrew Hertler, MD

Finding a Balance Between Standardization and Individualized Care in Pathways for Chronic Lymphocytic Leukemia

3:55 PM—4:40 PM

With the advent of individualized care in the management of chronic lymphocytic leukemia (CLL), diagnostic and therapeutic clinical pathways for this disease must take into account a patient’s clinical and genetic profile to inform appropriate treatment. However, as treatment recommendations become increasingly stratified, this presents a challenge for improving value at the population health level. Thus, CLL provides a case example of how to find the right balance among the goals of the Triple Aim—standardizing care, reducing costs, and optimizing individual

patient outcomes. This session will discuss how applying multiple stakeholder perspectives to the design and implementation of clinical pathways for disease states like CLL can facilitate the achievement of the Triple Aim by integrating patient perspectives with those of payers and providers. The role of pathways in helping healthcare providers navigate complex therapeutic landscapes will also be discussed.

KEYNOTE

The COME HOME Program: Building a Foundation for Provider-Developed Clinical Pathways and the Oncology Care Model

4:40 PM—5:25 PM

In 2012, Dr. Barbara McAneny was awarded a \$19.76 million grant by the Center for Medicare & Medicaid Innovation (CMS/CMMI) to develop a community oncology medical home model and implement that model in seven practices across the country. The model proved very successful in improving patient care, outcomes, and satisfaction while dramatically reducing costs, and it led to the evolution of the Oncology Care Model, now adopted by hundreds of practices and multiple payers across the country. Dr. McAneny, now President-Elect of the American Medical Association (AMA), will share insights and best practices from her experience as one of the earliest adopters of clinical pathways. Dr. McAneny will also outline her plans to help extend a value-based approach to other areas of medicine as AMA President.

Faculty: Barbara L. McAneny, MD, MACP, FASCO

Exhibit Hall Grand Opening Reception

5:25 PM—6:55 PM

COMPLIMENTARY REFRESHMENTS FOR ALL ATTENDEES.



Scientific Agenda

PRACTICAL IMPLEMENTATION OF PATHWAYS

Saturday, October 27

Registration and Breakfast with the Exhibitors

7:40 AM—8:40 AM

Opening Remarks

8:50 AM—9:00 AM

Patient Navigation Along a Clinical Pathway: Supporting Multidisciplinary Care Coordination to Improve Clinical Outcomes

9:00 AM—9:45 AM

Research shows that patient outcomes, costs, and healthcare resource utilization are improved if Oncology Nurse Navigators are enrolled and engaged in the clinical pathways development and utilization process. Navigators ensure that patients are informed and supported throughout the course of care and are essential in the support of care coordination across the multidisciplinary team. Thus, pathways must be developed so they are accessible to all members of the healthcare team, not just physicians. This session will discuss the vital role that Nurse Navigators play in facilitating patient education, engagement, and adherence to clinical pathways, emphasizing the importance of considering multidisciplinary perspectives in pathway design and implementation.

Faculty: Alan Balch, PhD; Deborah Christensen, MSN, APRN, AOCNS, HNB-BC

Optimizing Therapeutic Placement of Biosimilars in Clinical Pathways

9:45 AM—10:30 AM

With the rising costs of biologics, guiding providers to use available biosimilars—which are both efficacious and cost-effective—could help attenuate increasing healthcare costs. Multiple

biosimilars have been approved over the past year, with many more in development, and their introduction is estimated to save up to \$66 billion by the year 2024. However, the integration of biosimilars into clinical pathways requires weighing their efficacy and economic benefit against potential increased administrative burden and resistance from care providers. This session will explore key considerations for incorporating newly approved biosimilars into clinical pathways and provide insight into addressing challenges in biosimilar uptake.

Real-World Experiences Developing, Implementing, and Evaluating Clinical Pathway Programs: Part I

10:30 AM—11:30 AM

With the many clinical pathway programs currently in use, how do you determine which ones will work best for your organization? Learn from the unique successes and challenges of your peers during a series of candid exchanges at the Congress. Representatives from four health systems, each possessing unique pathway programs, will offer real-world perspectives on the similarities and differences in pathway processes across institutions, including:

- Rationale and goals for implementing pathways
- Determining third-party vendor or internal development (buy or build)
- Pathway committee selection
- Pathway maintenance
- Navigating reimbursement
- Leveraging payer contracts
- Addressing administrative burdens
- Gaining physician buy-in and adoption

Faculty: Linda Bosserman, MD, FASCO, FACP; Stephen B. Edge, MD, FACS, FASCO

How Clinical Pathways Can Support the Adoption of Newly Emerging Therapies for Advanced Hodgkin's Lymphoma

11:30 AM—12:15 PM

In order for clinical pathways to evolve with the latest therapeutic advances, stakeholders must be open to rapidly incorporating newly

available treatments into practice. Advanced Hodgkin's lymphoma (aHL) has long been managed with an effective but often poorly tolerated chemotherapeutic regimen. However, alternative first-line treatments may be on the horizon in aHL, including therapies previously approved only for patients with recurrent disease. As these treatments become available, incorporating them into clinical pathways will play an essential role in ensuring uptake among providers and reducing care disparities. This session will highlight the need for pathways to reflect the latest clinical data as well as the role of clinical pathways in supporting care providers and other stakeholders in their adoption of newly emerging therapies.



Lunch Innovation Theater

12:15 PM—1:30 PM

(NON-ACCREDITED)

COMPLIMENTARY LUNCH. SEATING IS LIMITED.

Real-World Experiences Developing, Implementing, and Evaluating Clinical Pathway Programs: Part II

1:40 PM—2:40 PM

This session is a continuation of the candid exchange on pathways, offering real-world perspectives on the similarities and differences in pathway processes across institutions to help you determine how to move your own organization's pathways program forward.

Faculty: David Hughes; Michael A. Savin, MD

Real-World Experience Round Table

2:40 PM—3:10 PM

Faculty: Linda Bosserman, MD, FASCO, FACP;
Stephen B. Edge, MD, FACS, FASCO; David
Hughes; Michael A. Savin, MD

FEATURED SESSION

Quality Reporting in the Era of Clinical Pathways: Learning from the Oncology Care Model

3:10 PM—3:55 PM

In an effort to improve the delivery of cancer care, the Centers for Medicare & Medicaid Services (CMS), in partnership with oncologists, other providers, states, and commercial plans, launched the Oncology Care Model (OCM) in 2016. The first data from participating practices made available last year has shown that OCM adherence yielded financial benefits, motivated practice change, and increased the alignment of care with patient interests. However, challenges persist with reporting, data analysis, and physician adoption. This session will review the key findings from OCM's first year, discuss how these findings will inform the model's approach going forward, and provide insight into how clinical pathways can support providers in their quality metrics reporting requirements.

CMS representative invitation extended

Exhibit Hall Reception and Conversation with Congress Committee

3:55 PM—5:55 PM

This is where the real conversation takes place. Join your peers in the Exhibit Hall to continue discussing what you learned throughout the day and engage in an integrated exchange with providers, payers, and pathway developers.

COMPLIMENTARY REFRESHMENTS FOR ALL ATTENDEES.

Scientific Agenda

MEASUREMENT & SUCCESSFUL OUTCOMES

Sunday, October 28

Coffee & Conversation

8:10 AM–8:40 AM

Meet informally over a continental breakfast with Congress faculty and participants to discuss your outstanding questions and absorb best practices, ideas, and insight.

Opening Remarks

8:50 AM–9:00 AM

How Do We Measure Whether Pathways are Working? Defining Successful Outcomes and Demonstrating ROI of Clinical Pathways

9:00 AM–9:45 AM

The implementation of clinical pathways is often associated with initial costs that arise from the development and maintenance of a pathways program. Thus, it is essential to demonstrate the return on investment (ROI) of clinical pathways in order to support their adoption and continued adherence. While pathways programs are associated with the accrual of significant cost savings over time, ROI considerations in this era of value-based care extend beyond the financial to incorporate improvements in care quality, resource utilization, and patient outcomes. But how can such a comprehensive ROI that satisfies all stakeholder needs be determined? This session will offer insight into the multiple aspects that comprise the clinical pathways ROI and how to extract ROI information from your healthcare system or practice's clinical data to demonstrate the unique benefits of pathways for all stakeholders.

Faculty: Ray Page, DO, PhD, FACOI

Maintaining Pathways in the Rapidly Changing Treatment Landscape for Non-Small Cell Lung Cancer

9:45 AM–10:30 AM

Expansion of the therapeutic landscape can lead to practice variations that result in rising care costs and suboptimal patient outcomes. This issue is clearly highlighted in the management of non-small cell lung cancer (NSCLC), with a variety of biomarkers and targeted therapies now directing individualized care based on a given patient's clinical presentation. Clinical pathways for NSCLC have the potential to promote individualized treatment while reducing resource utilization and costs, but must be continually revised as new approvals and guideline recommendations emerge. This session will use NSCLC to illustrate the inherent challenges of keeping pathways updated in an area with rapid innovation and the need to balance clinical innovations against rising care costs.



Tools and Platforms to Support Data Analysis for Pathway Development and Evaluation

10:30 AM–11:15 AM

Current clinical pathways are largely based on generalized measures such as evidence-based guidelines and consensus best practices. Yet electronic health records (EHR) contain a tremendous amount of data that, when operationalized, provide valuable information about the quality of care delivered as well as areas for improvement. A variety of technologies have been developed that allow practices and healthcare systems to extract meaningful outcomes from their own patient data and apply that information to subsequent care decisions. This session will highlight the platforms and tools now available for applying a more data-driven approach to informing the development and analysis of clinical pathways in order to continually improve patient care.

Faculty: Andrew Norden, MD, MPH, MBA; Gary Palmer, MD, JD, MBA, MPH

Evolution of the Pathway Development Marketplace

11:15 AM–12:00 PM

This is a dynamic time in the field of pathway development, as the vendor landscape transforms in the wake of a number of mergers and acquisitions that have occurred over the past year. With formerly distinct organizations consolidating under one umbrella, knowledge and resource sharing is poised to alter the pathway development process and increase alignment among available programs. In this session, find out what these changes might mean for your healthcare system or practice, and how they will shape the overall direction of value-based care in the future.

Lunch Pick-Up

12:00 PM–12:15 PM

Town Hall: Working Lunch

12:15 PM–1:15 PM

There's one final session that brings everyone together—join your 2018 Steering Committee for a roll-up-your-sleeves session that connects the dots on the previous days of programming, burning questions left unanswered, and topics left unaddressed. This is a can't-miss session and discussion that will leave you prepared to apply what you learned back at the office on Monday.

Faculty: Alan Balch, PhD; Aymen Elfiky, MD, MSc, MBA; Joan S. McClure, MS; Sandeep “Bobby” Reddy, MD; Robin T. Zon, MD, FACP, FASCO

Closing Remarks

1:15 PM–1:25 PM



Accreditation

Activity Overview

The Clinical Pathways Congress will occur from October 26–28, 2018 at the Westin Waterfront Boston in Boston, MA. A question-and-answer session with the faculty will follow each presentation.

To be eligible for documentation of credit, participants must complete the online evaluation form at www.nacme.com. All individuals who participate in the conference and submit the completed evaluation form online may immediately print their documentation of credit.

For questions regarding this educational activity, please call 609-371-1137.

See the registration rates section of the website for fee information.

Cancellation Policy

Cancellation requests must be received in writing and postmarked by September 10, 2018. All cancellations via email must be submitted by this date to sdonato@hmpglobal.com. Cancellations received by September 10, 2018 will receive a refund minus a \$100 processing fee. Registrants wishing to cancel may send someone to take their place without penalty if they send a written request with the replacement person's name by August 31, 2018. No refunds will be issued after September 10, 2018. If you do not cancel and do not attend the event, you are still responsible for the full payment.

Cancellations for hotel and transportation must

be handled by the individual registrant directly with the hotel, airline, and/or other company.

No refunds are offered for classes that may be suspended or shortened due to weather or other conditions or circumstances beyond HMP's control.

Learning Objectives

After attending the Clinical Pathways Congress 2018 meeting, participants should be able to:

- 1 Outline the opportunities and challenges associated with using clinical pathways as a foundation for value-based care
- 2 Examine the roles and responsibilities of payers, providers, and pathway developers in creating and implementing clinical pathways
- 3 Contribute to the effective implementation of clinical pathways to optimize quality of care, cost efficiency, and health outcomes

Intended Learners

This activity is designed for directors of oncology practice programs and cancer centers, oncologists, hematologists, commercial and government payers, pathway development executives, reimbursement specialists, specialty pharmacists, HEOR specialists, and other healthcare professionals interested in learning how to implement, integrate, and measure treatment pathways.

Accreditation



In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE

This continuing nursing education activity awards 12.25 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 12.25 contact hours.

CPE

This activity is approved for 12.25 contact hours (1.225 CEU) of continuing pharmacy education. (UAN J0006201-0000-18-003-LO1-P)

Additional UANs to be determined.

Each of these educational activities is a knowledge-based activity.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

*Contact hours subject to change.

ADA Statement

North American Center for Continuing Medical Education complies with the legal requirements of the Americans with Disabilities Act, and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved.



Provided by North American Center for Continuing Medical Education, LLC, an HMP Company.

Boston, MA



Hotel & Travel


The Westin Boston Waterfront

425 Summer Street
Boston, MA 02210

Special Room Rate: **\$299 per night + tax**

To reserve your room, please call 866.500.0167
or visit clinicalpathwayscongress.com/hotel.

The group room block cutoff date is
Monday, September 17, 2018. Rooms are available
on a first-come, first-served basis.



Registration Form

FIRST NAME	LAST NAME	DEGREE/CREDENTIALS		
TITLE		COMPANY/ORGANIZATION/PRACTICE NAME		
ADDRESS	CITY	STATE	ZIP	COUNTRY
PHONE		FAX		
EMAIL (Confirmations will be sent via email.)		NPI/LICENSE NUMBER		

Professional Category

- ☐ MD ☐ DO ☐ NP ☐ PA ☐ MSN/BN/RN ☐ Pharmacist
☐ Administrator ☐ Industry ☐ Consultant ☐ None ☐ Government
☐ Pathway Development Professional ☐ Reimbursement Specialist/Oncology Practice Management
☐ Other _____

Specialty

- ☐ Oncology ☐ Oncology/Hematology ☐ N/A ☐ Other _____

Are you currently using clinical pathways in your practice or organization?

- ☐ No ☐ No, but we are planning to use them ☐ We are in the process of developing one
☐ Yes, we recently implemented one ☐ Yes, we have multiple in place

If yes, what is your biggest challenge associated with clinical pathways? _____

In which care setting is the majority of your time spent?

- ☐ Hospital ☐ Office-based ☐ Cancer clinic/center ☐ Research ☐ N/A ☐ Other _____

Please select your registration type:

- ☐ Clinician/Provider Executive ☐ Administrator/Payer ☐ Pathway Development Executive

☐ Early Bird Rate Until June 29 \$629	☐ Onsite Rate Oct. 6–Onsite \$879	3 Ways to Register ☐ Online clinicalpathwayscongress.com ☐ Call 844.730.4052 ☐ Mail your registration form with payment to: HMP 70 East Swedesford Road, Suite 100 Malvern, PA 19355
☐ Advance Rate June 30–Aug. 17 \$679	☐ Non-Healthcare Provider/Consultant/Industry Anytime Rate \$2,999	
☐ Standard Rate Aug. 18–Oct. 5 \$779		
Total Payment Enclosed \$ _____		

Please Note: Your conference registration may already be included as part of your company's Sponsorship Package.
If you need confirmation before moving forward, please contact Jeff Hennessy, Jr. at 732.865.5823 or jhennessyjr@hmpglobal.com.

Method of Payment (Please choose from the following options)

- ☐ **Check made payable to HMP.** All checks must be drawn on a U.S. bank in U.S. funds.
In memo line, please note "Registration for Clinical Pathways Congress." Mail to HMP, 70 E. Swedesford Road, Suite 100, Malvern, PA 19355.

- ☐ **MasterCard** ☐ **Visa** ☐ **Discover** ☐ **American Express**

NAME ON CARD	CREDIT CARD NUMBER	
EXPIRATION DATE	SECURITY CODE	BILLING POSTAL CODE
SIGNATURE OF THE CARDHOLDER (REQUIRED)		

Cancellation Policy Cancellation requests must be received in writing and postmarked by September 10, 2018. All cancellations via email must be submitted by this date to sdonato@hmpglobal.com. Cancellations received by September 10, 2018 will receive a refund minus a \$100 processing fee. Registrants wishing to cancel may send someone to take their place without penalty if they send a written request with the replacement person's name by August 31, 2018. No refunds will be issued after September 10, 2018. If you do not cancel and do not attend the event, you are still responsible for the full payment.



CLINICAL PATHWAYS CONGRESS

You asked. We listened.

In 2018, the
pathways meeting
gets practical.



Recognized by the American Society of Clinical Oncology®

OCTOBER 26–28, 2018
WESTIN BOSTON WATERFRONT
BOSTON

Reserve your place today:
clinicalpathwayscongress.com

AN **HMP** EVENT



Get Practical
on Pathways

The meeting focused
on the practical
implementation, utilization,
and measurement of
oncology clinical pathways.

OCTOBER 26–28, 2018

Boston



CLINICAL
PATHWAYS
CONGRESS

ENDORSED BY

ASCO
AMERICAN SOCIETY OF CLINICAL ONCOLOGY